<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 and its receptor <z:chebi fb="4" ids="48705">agonist</z:chebi>-exendin-4 (Ex-4) have been shown to provide beneficial effects for <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular diseases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>This study investigated the effects of Ex-4 on <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> in rats </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Anesthetized male rats were once treated with Ex-4 (5 Î¼g/kg, i.v.) 1 h before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in the absence and/or presence of 5-hydroxydecanoic acid (5-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>, 10 mg/kg, i.v., a specific inhibitor of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> ATP-sensitive <z:chebi fb="120" ids="26216">potassium</z:chebi> [KATP] channels) which were once injected 10 min before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>And then subjected to <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> for 30 min </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0004308'>Ventricular arrhythmias</z:hpo> were assessed </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: During the 30-min <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, Ex-4 significantly reduced the incidence of <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>) (p &lt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>The duration of <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> (VT) + <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>, the number of VT + <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> episodes and the severity of <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> were <z:hpo ids='HP_0000001'>all</z:hpo> significantly reduced by Ex-4 compared to those in <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischemia</z:e> group (p &lt; 0.05 for <z:hpo ids='HP_0000001'>all</z:hpo>) </plain></SENT>
<SENT sid="7" pm="."><plain>Administration of 5-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> abolished the protective effects of Ex-4 on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> incidence, the duration of VT + <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>, the number of VT + <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> episodes and the severity of <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> (p &lt; 0.05 for <z:hpo ids='HP_0000001'>all</z:hpo>) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: This study suggested that Ex-4 could attenuate <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> in rats in which <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> KATP channels may be involved </plain></SENT>
</text></document>